|
|
|
Vascularized organ allografts are rapidly destroyed by host immune cells that are recruited along chemokine gradients. Among chemokines, Regulated on Activation, Normal T-cell Expressed and Secreted (RANTES) CC chemokine ligand (CCL5) and monocyte chemoattractant protein (MCP)-1 (CCL2) are upregulated in rejecting cardiac allografts. To antagonize these chemokines, the authors constructed adenoviral vectors expressing NH2-terminal deletion (8ND) mutants of the respective genes.
Their results are published in Gene Therapy (Vol. 13, pp. 1104–1109). The results suggest a role for anti-chemokine gene therapy as an adjuvant therapy in heart transplantation. Correspondence: Professor G Vassalli, Department of Cardiology, Centre Hospitalier Universitaire Vaudois (CHUV), rue du Bugnon, 1011 Lausanne, Switzerland.
E-mail: giuseppe.vassalli@chuv.hospvd.ch Abstract available online. Table of contents with links to abstracts (free for everyone) and full text (for members only) available at TOC online. (C) Gene Therapy. Posted by: Tressie Dalaya
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|